Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli.

Aguilar-Yáñez JM, Portillo-Lara R, Mendoza-Ochoa GI, García-Echauri SA, López-Pacheco F, Bulnes-Abundis D, Salgado-Gallegos J, Lara-Mayorga IM, Webb-Vargas Y, León-Angel FO, Rivero-Aranda RE, Oropeza-Almazán Y, Ruiz-Palacios GM, Zertuche-Guerra MI, DuBois RM, White SW, Schultz-Cherry S, Russell CJ, Alvarez MM.

PLoS One. 2010 Jul 22;5(7):e11694. doi: 10.1371/journal.pone.0011694.

2.

Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus.

Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, King LR, Ross TM, Golding H.

PLoS One. 2010 Jul 12;5(7):e11548. doi: 10.1371/journal.pone.0011548.

3.

The receptor-binding domain of influenza virus hemagglutinin produced in Escherichia coli folds into its native, immunogenic structure.

DuBois RM, Aguilar-Yañez JM, Mendoza-Ochoa GI, Oropeza-Almazán Y, Schultz-Cherry S, Alvarez MM, White SW, Russell CJ.

J Virol. 2011 Jan;85(2):865-72. doi: 10.1128/JVI.01412-10. Epub 2010 Nov 10.

4.

Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine.

Skibinski DA, Hanson BJ, Lin Y, von Messling V, Jegerlehner A, Tee JB, Chye de H, Wong SK, Ng AA, Lee HY, Au B, Lee BT, Santoso L, Poidinger M, Fairhurst AM, Matter A, Bachmann MF, Saudan P, Connolly JE.

PLoS One. 2013 Oct 18;8(10):e76571. doi: 10.1371/journal.pone.0076571. eCollection 2013.

5.

Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model.

Kreijtz JH, Süzer Y, Bodewes R, Schwantes A, van Amerongen G, Verburgh RJ, de Mutsert G, van den Brand J, van Trierum SE, Kuiken T, Fouchier RA, Osterhaus AD, Sutter G, Rimmelzwaan GF.

J Gen Virol. 2010 Nov;91(Pt 11):2745-52. doi: 10.1099/vir.0.024885-0. Epub 2010 Aug 18.

PMID:
20719991
6.

Immunogenicity and safety of H1N1 influenza hemagglutinin protein expressed in a baculovirus system.

Na HN, Kim KH, Song MK, Park HL, Lee EY, Shim SH, Park S, Nam JH.

Microbiol Immunol. 2013 Sep;57(9):660-4. doi: 10.1111/1348-0421.12079.

7.

Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice.

Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, Gao Y, Tan W, Ruan L.

Virol J. 2012 Dec 29;9:322. doi: 10.1186/1743-422X-9-322.

8.

Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.

Hossain MJ, Bourgeois M, Quan FS, Lipatov AS, Song JM, Chen LM, Compans RW, York I, Kang SM, Donis RO.

Clin Vaccine Immunol. 2011 Dec;18(12):2010-7. doi: 10.1128/CVI.05206-11. Epub 2011 Oct 26.

9.

Yeast expressed recombinant Hemagglutinin protein of novel H1N1 elicits neutralising antibodies in rabbits and mice.

Athmaram TN, Saraswat S, Santhosh SR, Singh AK, Suryanarayana WS, Priya R, Gopalan N, Parida M, Rao PV, Vijayaraghavan R.

Virol J. 2011 Nov 29;8:524. doi: 10.1186/1743-422X-8-524.

10.

A plant-produced influenza subunit vaccine protects ferrets against virus challenge.

Mett V, Musiychuk K, Bi H, Farrance CE, Horsey A, Ugulava N, Shoji Y, de la Rosa P, Palmer GA, Rabindran S, Streatfield SJ, Boyers A, Russell M, Mann A, Lambkin R, Oxford JS, Schild GC, Yusibov V.

Influenza Other Respir Viruses. 2008 Jan;2(1):33-40. doi: 10.1111/j.1750-2659.2008.00037.x.

11.

Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines.

Khurana S, Larkin C, Verma S, Joshi MB, Fontana J, Steven AC, King LR, Manischewitz J, McCormick W, Gupta RK, Golding H.

Vaccine. 2011 Aug 5;29(34):5657-65. doi: 10.1016/j.vaccine.2011.06.014. Epub 2011 Jun 23.

12.

Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity.

Hütter J, Rödig JV, Höper D, Seeberger PH, Reichl U, Rapp E, Lepenies B.

J Immunol. 2013 Jan 1;190(1):220-30. doi: 10.4049/jimmunol.1201060. Epub 2012 Dec 5.

13.

Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.

Khurana S, Verma S, Verma N, Crevar CJ, Carter DM, Manischewitz J, King LR, Ross TM, Golding H.

J Virol. 2011 Feb;85(3):1246-56. doi: 10.1128/JVI.02107-10. Epub 2010 Nov 17.

14.

Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.

Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, Dudman SG, Kawaoka Y, Kent SJ, Stinchcomb DT, Osorio JE, Friedrich TC.

J Virol. 2014 Nov;88(22):13418-28. doi: 10.1128/JVI.01219-14. Epub 2014 Sep 10.

15.

Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.

Bragstad K, Martel CJ, Thomsen JS, Jensen KL, Nielsen LP, Aasted B, Fomsgaard A.

Influenza Other Respir Viruses. 2011 Jan;5(1):13-23. doi: 10.1111/j.1750-2659.2010.00177.x. Epub 2010 Nov 3.

16.

An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination.

Schmeisser F, Vodeiko GM, Lugovtsev VY, Stout RR, Weir JP.

Vaccine. 2010 Mar 11;28(12):2442-9. doi: 10.1016/j.vaccine.2009.12.079. Epub 2010 Jan 12.

PMID:
20074687
17.

Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.

Shoji Y, Chichester JA, Jones M, Manceva SD, Damon E, Mett V, Musiychuk K, Bi H, Farrance C, Shamloul M, Kushnir N, Sharma S, Yusibov V.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:41-50. Epub 2011 Jan 1.

PMID:
21266846
18.

Cell-free production of trimeric influenza hemagglutinin head domain proteins as vaccine antigens.

Welsh JP, Lu Y, He XS, Greenberg HB, Swartz JR.

Biotechnol Bioeng. 2012 Dec;109(12):2962-9. doi: 10.1002/bit.24581. Epub 2012 Aug 16.

PMID:
22729608
19.

Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines.

Lu Y, Welsh JP, Swartz JR.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):125-30. doi: 10.1073/pnas.1308701110. Epub 2013 Dec 16.

20.

Glycosylation at 158N of the hemagglutinin protein and receptor binding specificity synergistically affect the antigenicity and immunogenicity of a live attenuated H5N1 A/Vietnam/1203/2004 vaccine virus in ferrets.

Wang W, Lu B, Zhou H, Suguitan AL Jr, Cheng X, Subbarao K, Kemble G, Jin H.

J Virol. 2010 Jul;84(13):6570-7. doi: 10.1128/JVI.00221-10. Epub 2010 Apr 28.

Supplemental Content

Support Center